title: Reply to the letter to the editor 'Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy' by Tannock et al.
authors.affiliation: Clinical Oncology Academic Unit, Royal Marsden NHS Foundation Trust, Sutton, UK chris.parker@icr.ac.uk.
authors.forename: C
authors.initials: C
authors.lastname: Parker
authors.affiliation: Department of Oncology and Hematology, Kantonsspital, St Gallen, Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Gillessen
authors.affiliation: Department of Urology, RWTH University Aachen, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Heidenreich
authors.affiliation: Department of Clinical Oncology, Academic Unit, Royal Marsden NHS Trust, Sutton, UK.
authors.forename: A
authors.initials: A
authors.lastname: Horwich
mesh_terms: D006801:Humans; D008297:Male; D011467:Prostate / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy*